https://www.selleckchem.com/pr....oducts/tofa-rmi14514
In metastatic melanoma, cyclin D-CDK4/6-INK4-Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of cyclin-dependent kinase 4 (CDK4) inhibitors. In this phase I-II study, we aimed to establish the MTD of palbociclib when added to vemurafenib. Patients with metastatic melanoma harboring loss and expression were included and stratified into two groups according to previous BRAF inhibitor treatment (nostrata 1; yesstrata 2). Treatment comprised palbociclib once daily for 14 days followe
Like
Comment
Share
